BNB PLUS CORP. (BNBX) — Quarterly Report

AI-Powered SEC Filing Analysis

Latest Quarterly Report Filed: 2026-05-15

Key Insights

BNB Plus Corp operates in DNA-based biotechnology with multiple revenue segments including therapeutic DNA production, DNA tagging/security products, and clinical laboratory services, indicating diversified business model exposure across healthcare and security markets.
The company shows recent executive compensation activity with stock option grants and warrant issuances dated October 2025 through December 2025, suggesting ongoing incentive alignment with management during the reporting period.
Filing structure indicates private placement capital raises occurred in October 2025 involving cash and digital assets (stablecoins), suggesting the company accessed alternative financing methods and may have cryptocurrency exposure on its balance sheet.
Multiple operating segments with revenue recognition at point-in-time for services including supply chain, R&D services, and large-scale DNA production suggest complex revenue recognition policies that warrant careful scrutiny of segment profitability and margins.

Want the newest filings?

This analysis covers the filing from 2026-05-15. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Quarterly Report filings

Filed: 2026-02-12

The company reported a 25% year-over-year increase in revenue for the Therapeutic DNA Production segment during Q1 2025, suggesting strong demand for its products.
The company's consulting arrangements with Ground Tunnel Capital LLC and Cypress Management LLC indicate strategic partnerships that could unlock new business opportunities.
The company raised $400,000 through an at-the-market offering in Q4 2025, which could provide additional capital to fund growth initiatives.

Other reports for BNB PLUS CORP.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.